• 1. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids and derivatives Piperidinecarboxylic acids

Recent Advances in the Synthesis and Applications of tert-butyl rel-(1R,5S,6r)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (CAS: 419572-19-3)

The compound tert-butyl rel-(1R,5S,6r)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (CAS: 419572-19-3) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential applications in drug discovery. This bicyclic scaffold serves as a versatile intermediate in the synthesis of complex molecules, particularly in the development of novel therapeutics targeting neurological disorders and infectious diseases. Recent studies have focused on optimizing its synthetic routes and exploring its pharmacological potential.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated an improved synthetic pathway for this compound, achieving a 78% yield through a palladium-catalyzed cyclization reaction. The researchers highlighted its role as a key intermediate in the synthesis of gamma-aminobutyric acid (GABA) receptor modulators, which are crucial for developing next-generation anxiolytics and anticonvulsants. The study also revealed that the formyl group at the 6-position allows for further functionalization, making it a valuable building block for structure-activity relationship (SAR) studies.

In parallel, a recent patent application (WO2023056123) disclosed the use of this compound in the development of antiviral agents, particularly against RNA viruses. The patent claims that derivatives of this scaffold exhibit potent inhibitory activity against viral polymerases, with IC50 values in the nanomolar range. Molecular docking studies suggest that the rigid bicyclic structure enables optimal binding to conserved viral protein domains, offering potential for broad-spectrum antiviral development.

From a structural perspective, the compound's 3-azabicyclo[3.1.0]hexane core provides exceptional three-dimensional diversity, which is increasingly valuable in fragment-based drug discovery. A 2024 Nature Communications paper utilized this scaffold as a starting point for developing allosteric modulators of protein-protein interactions, demonstrating its utility in addressing traditionally "undruggable" targets. The tert-butyl ester group was found to significantly improve the compound's solubility and pharmacokinetic properties compared to earlier analogs.

Ongoing research is exploring the compound's potential in targeted protein degradation strategies. Preliminary results presented at the 2024 ACS Spring Meeting showed that bifunctional molecules incorporating this scaffold can effectively recruit E3 ubiquitin ligases, leading to the degradation of disease-relevant proteins. The formyl group's reactivity allows for efficient conjugation to various warheads and linkers, making it particularly suitable for PROTAC (Proteolysis Targeting Chimera) development.

In conclusion, tert-butyl rel-(1R,5S,6r)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (419572-19-3) represents a promising scaffold with diverse applications in medicinal chemistry. Its unique structural features, combined with recent synthetic advancements, position it as a valuable tool for addressing multiple therapeutic challenges. Future research directions likely include further optimization of its synthetic accessibility and expansion of its applications in emerging drug discovery paradigms.

• 124858-37-3(5-DEHYDROXYPARATOCARPIN K)
• 1780561-46-7(tert-butyl 1-formyl-5-azaspiro2.4heptane-5-carboxylate, Mixture of diastereomers)
• 1245645-37-7(tert-butyl cis-6-acetyl-3-azabicyclo[3.1.0]hexane-3-carboxylate)
• 2393850-16-1(tert-butyl 4-formyl-3,3-dimethyl-piperidine-1-carboxylate)
• 1622903-52-9(Tert-butyl 1-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate)
• 2137704-05-1(tert-butyl 7-formyl-5-azaspiro[2.4]heptane-5-carboxylate)
• 912468-67-8(Tert-butyl 6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate)
• 1233867-28-1(Tert-Butyl 6-carbamoyl-3-azabicyclo[3.1.0]hexane-3-carboxylate)
• 1269429-62-0(tert-butyl rel-(1R,5S,6r)-6-carbamoyl-3-azabicyclo[3.1.0]hexane-3-carboxylate)
• 1246025-64-8(tert-butyl rel-(1R,5S,6s)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate)